Sep 17, 2020 9:00am EDT Qualigen Therapeutics Announces Filing of U.S. Provisional Patent Application for the Use of AS1411 to Prevent Viral Infections
Aug 31, 2020 9:00am EDT Qualigen Therapeutics Engages IRISYS LLC as GMP Manufacturer for AS1411 Drug Product
Aug 20, 2020 8:00am EDT Qualigen Therapeutics Announces Issuance of STARS™ Technology Patent by the U.S. Patent and Trademark Office
Aug 14, 2020 5:24pm EDT Qualigen Therapeutics Announces Business Highlights and First Quarter Fiscal Year 2021 Financial Results; Has $16 Million in Cash on Hand as of Today
Aug 06, 2020 3:59pm EDT Qualigen Therapeutics to Host Business Update Conference Call on August 18, 2020
Aug 04, 2020 4:05pm EDT Qualigen Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Aug 02, 2020 5:32pm EDT Qualigen Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jul 22, 2020 8:00am EDT Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville for RAS Interaction Inhibitor Drug Candidates
